Download Citation
Article Source:
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Carbognin L,
Pilotto S,
Milella M,
Vaccaro V,
Brunelli M,
et al.
(2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
PLOS ONE 10(6): e0130142.
https://doi.org/10.1371/journal.pone.0130142